SKB BIO (06990) rose more than 5% in morning trading. At the time of writing, the stock was up 4.71% to HK$444.2, with a turnover of HK$38.44 million. The move follows an announcement from Merck that its investigational TROP2 antibody-drug conjugate sac-TMT, licensed from SKB BIO, has successfully met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the Phase 3 TroFuse-005 study for patients with certain advanced or recurrent endometrial cancer. The therapy also delivered positive results on the key secondary endpoint of objective response rate (ORR).